BioCentury
ARTICLE | Clinical News

Global Blood expands Phase IIa of GBT440 to younger sickle cell patients

July 28, 2017 9:02 PM UTC

Global Blood Therapeutics Inc. (NASDAQ:GBT) expanded part A of the Phase IIa HOPE-KIDS 1 (GBT440-007) trial of oral GBT440 in about 41 pediatric patients with sickle cell disease to include a new cohort of children ages 6-11. The company said the expansion follows positive pharmacokinetic and safety data from a cohort of 7 adolescents ages 12-17 in part A of the trial. Global Blood expects data from the new cohort this year.

Part A of the trial is evaluating a single dose of 600 mg GBT440, with pharmacokinetics defined as the primary endpoint. The secondary endpoint of part A is safety...

BCIQ Company Profiles

Global Blood Therapeutics Inc.